Literature DB >> 4120848

Fibrinolysis in cholestatic jaundice.

A Jedrychowski, P Hillenbrand, A B Ajdukiewicz, S P Parbhoo, S Sherlock.   

Abstract

The fibrinolytic system was studied in primary biliary cirrhosis (16 patients) and large bile duct obstruction (10 patients, nine of whom had carcinoma). Plasma fibrinolysis (plasminogen activator activity) was decreased and fibrinogen increased in both groups of patients, particularly in those with large duct obstruction. These changes were related to the degree of cholestasis. Plasminogen activator activity was inversely related to serum triglyceride levels in patients with primary biliary cirrhosis. Urokinase inhibitors were decreased in both groups and antiplasmins increased in patients with large duct obstruction; fibrin/fibrinogen degradation products were normal in primary biliary cirrhosis and moderately increased in large duct obstruction. None of these fibrinolytic indices was related to the degree of cholestasis. Fibrinolytic activity and fibrinogen returned almost to normal levels after palliative surgery in the three patients with large duct obstruction who were studied. The decreased plasma fibrinolysis and increased fibrinogen may be due to altered lipid metabolism in cholestatic jaundice. In patients undergoing surgery for large duct obstruction there may be an increased risk of thrombosis.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4120848      PMCID: PMC1588651          DOI: 10.1136/bmj.1.5854.640

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  18 in total

1.  ANTIPLASMIN ACTIVITY OF BETA-LIPOPROTEIN.

Authors:  I M RIDING; D ELLIS
Journal:  J Atheroscler Res       Date:  1964 Mar-Apr

2.  The relationship between blood fibrinolytic activity, serum lipoproteins and serum cholesterol in atherosclerotic arterial disease.

Authors:  P J NESTEL
Journal:  Australas Ann Med       Date:  1960-08

3.  Severe thrombotic disease in a young man with bone marrow and skeletal changes and with a high content of an inhibitor in the fibrinolytic system.

Authors:  I M NILSSON; H KROOK; N H STERNBY; E SODERBERG; N SODERSTROM
Journal:  Acta Med Scand       Date:  1961-03

4.  The lipid composition of serum in patients with liver disease.

Authors:  G B PHILLIPS
Journal:  J Clin Invest       Date:  1960-11       Impact factor: 14.808

5.  Gonadal influences on plasma fibrin and fibrinolytic activity: a possible basis for the further analysis of some forms of coronary thrombosis.

Authors:  T GILLMAN; S S NAIDOO
Journal:  Endocrinology       Date:  1958-01       Impact factor: 4.736

6.  The fibrin plate method for estimating fibrinolytic activity.

Authors:  T ASTRUP; S MULLERTZ
Journal:  Arch Biochem Biophys       Date:  1952-10       Impact factor: 4.013

7.  [Factors of the fibrinolytic system in liver diseases].

Authors:  J van de Loo; G Schmiesing
Journal:  Thromb Diath Haemorrh       Date:  1965-11-15

8.  Simplified measurement of monoglycerides, diglycerides, triglycerides, and free fatty acids in biological samples.

Authors:  A Marzo; P Ghirardi; D Sardini; G Meroni
Journal:  Clin Chem       Date:  1971-03       Impact factor: 8.327

9.  Inactivation of human serum plasminogen antiactivator by synthetic fibrinolysis inducers.

Authors:  N Aoki; K N von Kaulla
Journal:  Thromb Diath Haemorrh       Date:  1969-11-15

10.  Quantitative estimation of split products of fibrinogen in human serum, relation to diagnosis and treatment.

Authors:  C Merskey; G J Kleiner; A J Johnson
Journal:  Blood       Date:  1966-07       Impact factor: 22.113

View more
  4 in total

1.  Fibrin deposition following bile duct injury limits fibrosis through an αMβ2-dependent mechanism.

Authors:  Nikita Joshi; Anna K Kopec; Jessica L Ray; Holly Cline-Fedewa; Atta Nawabi; Timothy Schmitt; Rance Nault; Timothy R Zacharewski; Cheryl E Rockwell; Matthew J Flick; James P Luyendyk
Journal:  Blood       Date:  2016-02-26       Impact factor: 22.113

Review 2.  Some clinical features of liver cell failure: an appraisal of their causes.

Authors:  A E Read
Journal:  Gut       Date:  1978-06       Impact factor: 23.059

3.  Endotoxaemia and renal failure in cirrhosis and obstructive jaundice.

Authors:  S P Wilkinson; H Moodie; J D Stamatakis; V V Kakkar; R Williams
Journal:  Br Med J       Date:  1976-12-11

4.  Antithrombin III, plasminogen and alpha 2 antiplasmin in jaundice. Clinical usefulness and prognostic significance.

Authors:  J J Rodzynek; D Urbain; P Leautaud; P Wettendorff; A Delcourt
Journal:  Gut       Date:  1984-10       Impact factor: 23.059

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.